Cargando…
Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial
BACKGROUND: Characterization of viruses in HIV-1 transmission pairs will help identify biological determinants of infectiousness and evaluate candidate interventions to reduce transmission. Although HIV-1 sequencing is frequently used to substantiate linkage between newly HIV-1 infected individuals...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047537/ https://www.ncbi.nlm.nih.gov/pubmed/21399681 http://dx.doi.org/10.1371/journal.pone.0016986 |
_version_ | 1782199041377959936 |
---|---|
author | Campbell, Mary S. Mullins, James I. Hughes, James P. Celum, Connie Wong, Kim G. Raugi, Dana N. Sorensen, Stefanie Stoddard, Julia N. Zhao, Hong Deng, Wenjie Kahle, Erin Panteleeff, Dana Baeten, Jared M. McCutchan, Francine E. Albert, Jan Leitner, Thomas Wald, Anna Corey, Lawrence Lingappa, Jairam R. |
author_facet | Campbell, Mary S. Mullins, James I. Hughes, James P. Celum, Connie Wong, Kim G. Raugi, Dana N. Sorensen, Stefanie Stoddard, Julia N. Zhao, Hong Deng, Wenjie Kahle, Erin Panteleeff, Dana Baeten, Jared M. McCutchan, Francine E. Albert, Jan Leitner, Thomas Wald, Anna Corey, Lawrence Lingappa, Jairam R. |
author_sort | Campbell, Mary S. |
collection | PubMed |
description | BACKGROUND: Characterization of viruses in HIV-1 transmission pairs will help identify biological determinants of infectiousness and evaluate candidate interventions to reduce transmission. Although HIV-1 sequencing is frequently used to substantiate linkage between newly HIV-1 infected individuals and their sexual partners in epidemiologic and forensic studies, viral sequencing is seldom applied in HIV-1 prevention trials. The Partners in Prevention HSV/HIV Transmission Study (ClinicalTrials.gov #NCT00194519) was a prospective randomized placebo-controlled trial that enrolled serodiscordant heterosexual couples to determine the efficacy of genital herpes suppression in reducing HIV-1 transmission; as part of the study analysis, HIV-1 sequences were examined for genetic linkage between seroconverters and their enrolled partners. METHODOLOGY/PRINCIPAL FINDINGS: We obtained partial consensus HIV-1 env and gag sequences from blood plasma for 151 transmission pairs and performed deep sequencing of env in some cases. We analyzed sequences with phylogenetic techniques and developed a Bayesian algorithm to evaluate the probability of linkage. For linkage, we required monophyletic clustering between enrolled partners' sequences and a Bayesian posterior probability of ≥50%. Adjudicators classified each seroconversion, finding 108 (71.5%) linked, 40 (26.5%) unlinked, and 3 (2.0%) indeterminate transmissions, with linkage determined by consensus env sequencing in 91 (84%). Male seroconverters had a higher frequency of unlinked transmissions than female seroconverters. The likelihood of transmission from the enrolled partner was related to time on study, with increasing numbers of unlinked transmissions occurring after longer observation periods. Finally, baseline viral load was found to be significantly higher among linked transmitters. CONCLUSIONS/SIGNIFICANCE: In this first use of HIV-1 sequencing to establish endpoints in a large clinical trial, more than one-fourth of transmissions were unlinked to the enrolled partner, illustrating the relevance of these methods in the design of future HIV-1 prevention trials in serodiscordant couples. A hierarchy of sequencing techniques, analysis methods, and expert adjudication contributed to the linkage determination process. |
format | Text |
id | pubmed-3047537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30475372011-03-11 Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial Campbell, Mary S. Mullins, James I. Hughes, James P. Celum, Connie Wong, Kim G. Raugi, Dana N. Sorensen, Stefanie Stoddard, Julia N. Zhao, Hong Deng, Wenjie Kahle, Erin Panteleeff, Dana Baeten, Jared M. McCutchan, Francine E. Albert, Jan Leitner, Thomas Wald, Anna Corey, Lawrence Lingappa, Jairam R. PLoS One Research Article BACKGROUND: Characterization of viruses in HIV-1 transmission pairs will help identify biological determinants of infectiousness and evaluate candidate interventions to reduce transmission. Although HIV-1 sequencing is frequently used to substantiate linkage between newly HIV-1 infected individuals and their sexual partners in epidemiologic and forensic studies, viral sequencing is seldom applied in HIV-1 prevention trials. The Partners in Prevention HSV/HIV Transmission Study (ClinicalTrials.gov #NCT00194519) was a prospective randomized placebo-controlled trial that enrolled serodiscordant heterosexual couples to determine the efficacy of genital herpes suppression in reducing HIV-1 transmission; as part of the study analysis, HIV-1 sequences were examined for genetic linkage between seroconverters and their enrolled partners. METHODOLOGY/PRINCIPAL FINDINGS: We obtained partial consensus HIV-1 env and gag sequences from blood plasma for 151 transmission pairs and performed deep sequencing of env in some cases. We analyzed sequences with phylogenetic techniques and developed a Bayesian algorithm to evaluate the probability of linkage. For linkage, we required monophyletic clustering between enrolled partners' sequences and a Bayesian posterior probability of ≥50%. Adjudicators classified each seroconversion, finding 108 (71.5%) linked, 40 (26.5%) unlinked, and 3 (2.0%) indeterminate transmissions, with linkage determined by consensus env sequencing in 91 (84%). Male seroconverters had a higher frequency of unlinked transmissions than female seroconverters. The likelihood of transmission from the enrolled partner was related to time on study, with increasing numbers of unlinked transmissions occurring after longer observation periods. Finally, baseline viral load was found to be significantly higher among linked transmitters. CONCLUSIONS/SIGNIFICANCE: In this first use of HIV-1 sequencing to establish endpoints in a large clinical trial, more than one-fourth of transmissions were unlinked to the enrolled partner, illustrating the relevance of these methods in the design of future HIV-1 prevention trials in serodiscordant couples. A hierarchy of sequencing techniques, analysis methods, and expert adjudication contributed to the linkage determination process. Public Library of Science 2011-03-02 /pmc/articles/PMC3047537/ /pubmed/21399681 http://dx.doi.org/10.1371/journal.pone.0016986 Text en Campbell et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Campbell, Mary S. Mullins, James I. Hughes, James P. Celum, Connie Wong, Kim G. Raugi, Dana N. Sorensen, Stefanie Stoddard, Julia N. Zhao, Hong Deng, Wenjie Kahle, Erin Panteleeff, Dana Baeten, Jared M. McCutchan, Francine E. Albert, Jan Leitner, Thomas Wald, Anna Corey, Lawrence Lingappa, Jairam R. Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial |
title | Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial |
title_full | Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial |
title_fullStr | Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial |
title_full_unstemmed | Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial |
title_short | Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial |
title_sort | viral linkage in hiv-1 seroconverters and their partners in an hiv-1 prevention clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047537/ https://www.ncbi.nlm.nih.gov/pubmed/21399681 http://dx.doi.org/10.1371/journal.pone.0016986 |
work_keys_str_mv | AT campbellmarys virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT mullinsjamesi virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT hughesjamesp virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT celumconnie virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT wongkimg virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT raugidanan virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT sorensenstefanie virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT stoddardjulian virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT zhaohong virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT dengwenjie virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT kahleerin virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT panteleeffdana virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT baetenjaredm virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT mccutchanfrancinee virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT albertjan virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT leitnerthomas virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT waldanna virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT coreylawrence virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT lingappajairamr virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial AT virallinkageinhiv1seroconvertersandtheirpartnersinanhiv1preventionclinicaltrial |